The HER Foundation leadership hosted a booth at SMFM 2023 medical conference and educated doctors about the importance of thiamin and brain health for HG patients. Our booth was right by the front doors, so we had a lot of visibility.
HER leadership Vvolunteered at our booth at the medical confence
Dr. Fejzo presented our genetic research
Dr. Fejzo presented, “Genome-wide association study meta-analysis of hyperemesis gravidarum confirms GDF15 and identifies additional risk loci.” The study is coauthored by Natàlia Pujol-Gualdo, PhD; Triin Laisk, PhD; Kimber MacGibbon, RN; Xinran Wang, PhD; and Nicholas Mancuso, PhD.
Objective: Hyperemesis Gravidarum (HG) occurs in ~2% of pregnancies and is associated with adverse maternal and fetal outcomes. It is highly heritable, thus elucidating genetic risk factors may lead to more effective treatments. Herein, we report results from the largest ever genome-wide association study (GWAS) of HG, comprised of 7,417 cases and 359,870 controls.
Study Design: We performed a meta-analysis of 5 independent studies: a multi-ancestry whole-exome sequencing study from the US and 4 GWASs of European ancestry from 23andMe customers, FinnGen, Estonian, and UK Biobanks.
Genetic loci in hCG and its receptor were not associated with HG in any of the analyses, providing no support for the historical hypothesis that the pregnancy hormone is the cause. Overall, this study contributes to our understanding of the biology of nausea and vomiting in pregnancy. This understand may lead to future research evaluating new treatment avenues. Of note, drugs targeting the GDF15 pathway have shown great promise in mitigating weight loss, loss of appetite, and vomiting in animal models. These drugs are currently in clinical trials in cancer cachexia, a disease with similar symptoms to HG. The strong link to this pathway in HG suggests these drugs, if safe, may hold great promise for treating HG in the future.
HER Foundation SMFM 2023 Booth
Kimber offers a tour of our booth for medical conferences.